Dapagliflozin

BreastfeedingGeriatricPediatric

FDA APPROVAL DATE: 01/08/2014

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Pioglitazone

PREGNANCY CATEGORY: C

Under investigation for treating COVID-19

See adverse reactions attributed to class:

Sodium-glucose co-transporter 2 (SGLT2) inhibitor

Contra-indicated in patients with severe renal impairment, end-stage renal disease, or undergoing dialysis.

Qtern is dapagliflozin and saxagliptin; Xigduo XR is dapagliflozin and metformin.

Dermatitis 

(2016): Mellander A+, Clin Drug Investig 36(11), 9251%

Eczema 

(2016): Mellander A+, Clin Drug Investig 36(11), 9251%

(2014): Kaku K+, Diabetes Ther 5(2), 4154%

Hyperhidrosis <1%

(package insert, 01/08/2014)

Hypersensitivity 

(2016): Mellander A+, Clin Drug Investig 36(11), 9255%

Peripheral edema (see also edema) 

(2009): Wilding JP+, Diabetes Care 32(9), 16568% (with insulin and oral antidiabetic agents)

Rash 

(2016): Mellander A+, Clin Drug Investig 36(11), 9251%

Urticaria / hives 

(2016): Mellander A+, Clin Drug Investig 36(11), 9251%

Xerostomia (dry mouth) 

(2009): Wilding JP+, Diabetes Care 32(9), 16568% (with insulin and oral antidiabetic agents)

Hypertension 

(2014): Strojek K+, Diabetes Ther 5(1), 2672–6% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20157% (with metformin)

Hypotension 

(2016): Skolnik N+, Postgrad Med 128(4), 356<1%

(2015): Cefalu WT+, Diabetes Care 38(7), 1218

(2009): List JF+, Diabetes Care 32(4), 650<2%

Anxiety 

(2009): Wilding JP+, Diabetes Care 32(9), 16568% (with insulin and oral antidiabetic agents)

Headache 

(2017): Dandona P+, Lancet Diabetes Endocrinol 5(11), 8644–6%

(2011): Nauck MA+, Diabetes Care 34(9), 20155% (with metformin)

(2009): Wilding JP+, Diabetes Care 32(9), 165613% (with insulin and oral antidiabetic agents)

Vertigo / dizziness 

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print2%

(2011): Nauck MA+, Diabetes Care 34(9), 20154% (with metformin)

Acidosis (includes lactic acidosis) 

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print [REVIEW]3% (life threatening in some patients)

Dehydration  

(2016): Skolnik N+, Postgrad Med 128(4), 356<1%

(2015): Cefalu WT+, Diabetes Care 38(7), 1218

Diabetic ketoacidosis 

(2019): Araki E+, Diabetes Obes Metab Nov, Epub ahead of print1–3%

(2018): Chou YM+, Medicine (Baltimore) 97(25) (1 case)

(2018): Dandona P+, Diabetes Care Oct, Epub ahead of print

(2018): Wiviott SD+, N Engl J Med Nov, Epub ahead of print

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print [REVIEW]6%

Dyslipidemia 2–3%

(2014): Strojek K+, Diabetes Ther 5(1), 267<3% (with glimepiride)

Euglycemic diabetic ketoacidosis 

(2021): Tsutsui E+, Cureus 13(7), e16085 (1 case / female)

(2019): Leader R+, BMJ Case Rep 12(9), e231104 (1 case)

Hypercalcemia  

(2017): Marques Vidas M+, Nefrologia Aug, Epub ahead of print

Hypoglycemia >10%

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print1%

(2019): Araki E+, Diabetes Obes Metab Nov, Epub ahead of print3–7% (severe)

(2019): Xu Y+, Nan Fang Yi Ke Da Xue Xue Bao (Chinese) 39(11), 13056% (with metformin and saglipti)

(2018): Mathieu C+, Diabetes Care Jul, Epub ahead of print

(2016): Skolnik N+, Postgrad Med 128(4), 3563–17%

(2015): Bailey CJ+, Diabet Med 32(4), 531<5%

(2015): Matthaei S+, Diabetes Care 38(3), 36513% (with metformin and sulfonylurea)

(2014): Ji L+, Clin Ther 36(1), 841%

(2013): Kaku K+, Diabetes Obes Metab 15(5), 432 (2 cases)

(2013): Nauck M+, Dtsch Med Wochenschr (German) 138 Suppl 1, S64%

(2013): Wilding JP+, Dtsch Med Wochenschr (German) 138 Suppl 1, S27 (with insulin)

(2012): Musso G+, Ann Med 44(4), 375 [REVIEW] (with insuliin)

(2012): Wilding JP+, Ann Intern Med 156(6), 405

(2011): Nauck MA+, Diabetes Care 34(9), 20153% (with metformin)

(2011): Strojek K+, Diabetes Obes Metab 13(10), 9287–8% (with glimepiride)

(2009): List JF+, Diabetes Care 32(4), 6506–10%

(2009): Wilding JP+, Diabetes Care 32(9), 165625–29% (with insulin and oral antidiabetic agents)

Hypovolemia 

(2016): Skolnik N+, Postgrad Med 128(4), 356<1%

(2015): Cefalu WT+, Diabetes Care 38(7), 1218

Serum creatinine increased 

(2016): Fioretto P+, Drugs Aging 33(7), 511 (transient)

Abdominal pain 

(2009): Wilding JP+, Diabetes Care 32(9), 16564% (with insulin and oral antidiabetic agents)

Constipation 2%

(2014): Kaku K+, Diabetes Ther 5(2), 4154%

Diarrhea 

(2016): Frias JP+, Lancet Diabetes Endocrinol 4(12), 1004

(2014): Strojek K+, Diabetes Ther 5(1), 267<3% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20155% (with metformin)

Dyspepsia / functional dyspepsia / gastroparesis 

(2014): Strojek K+, Diabetes Ther 5(1), 267<3% (with glimepiride)

Gastroenteritis 

(2011): Nauck MA+, Diabetes Care 34(9), 20153% (with metformin)

Nausea 3%

(2017): Lundkvist P+, Diabetes Obes Metab 19(9), 1276 (with exenatide)

(2016): Frias JP+, Lancet Diabetes Endocrinol 4(12), 1004

(2009): Wilding JP+, Diabetes Care 32(9), 16564–13% (with insulin and oral antidiabetic agents)

Vomiting  

(2009): Wilding JP+, Diabetes Care 32(9), 165613% (with insulin and oral antidiabetic agents)

Balanitis (glans penile inflammation) 

(2017): Esteban-Jimenez O+, Semergen Nov , Epub ahead of print Balanoposthitis/Candida balanitis6%

(2012): Bolinder J+, J Clin Endocrinol Metab 97(3), 1020 (with metformin)

Dysuria 

(package insert, 01/08/2014)

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print3%

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print2%

Genital mycotic infection 3–8%

(particularly in women)

(2018): Wiviott SD+, N Engl J Med Nov, Epub ahead of print

(2017): Jabbour S+, Diabetes Obes Metab Sep, Epub ahead of print6%

(2017): Johnston R+, Health Technol Assess 21(2), 1 [REVIEW]

(2016): Fioretto P+, Drugs Aging 33(7), 511

(2016): Skolnik N+, Postgrad Med 128(4), 3563–10%

(2016): Yang W+, J Diabetes 8(6), 796<2%

(2015): Bailey CJ+, Diabet Med 32(4), 531

(2015): Cefalu WT+, Diabetes Care 38(7), 1218

(2015): Filippatos TD+, Ther Adv Endocrinol Metab 6(1), 29 [REVIEW]

(2015): Hinnen D, Ther Adv Endocrinol Metab 6(3), 92

(2015): Mathieu C+, Diabetes Care 38(11), 20095% (with metformin and saxagliptin)

(2015): Matthaei S+, Diabetes Care 38(3), 3656% (with metformin and sulfonylurea)

(2015): Matthaei S+, Diabetes Obes Metab 17(11), 107510% (with metformin and sulfonylurea)

(2015): Vivian EM, Am J Health Syst Pharm 72(5), 361 [REVIEW]

(2014): Anderson SL, Ther Adv Drug Saf 5(6), 242 [REVIEW]

(2014): Aylsworth A+, Ann Pharmacother 48(9), 1202 [REVIEW]

(2014): Moses RG+, Australas Med J 7(10), 405 [REVIEW]

(2014): Plosker GL, Drugs 74(18), 2191 [REVIEW]

(2014): Strojek K+, Diabetes Ther 5(1), 2675–9% (with glimepiride)

(2014): Wilding JP+, Diabetes Obes Metab 16(2), 1247–14%

(2013): Albarran OG+, Med Clin (Barc) (Spanish) 141 Suppl 2, 36 [REVIEW]

(2013): Hinneburg I, Med Monatsschr Pharm (German) 36(4), 128 [REVIEW]

(2013): Johnsson KM+, J Diabetes Complications 27(5), 479

(2013): Kaku K+, Diabetes Obes Metab 15(5), 432

(2013): Nauck M+, Dtsch Med Wochenschr (German) 138 Suppl 1, S6

(2013): Strojek K+, Dtsch Med Wochenschr (German) 138 Suppl 1, S164–7% (with glimepiride)

(2013): Wilding JP+, Dtsch Med Wochenschr (German) 138 Suppl 1, S27

(2012): Bolinder J+, J Clin Endocrinol Metab 97(3), 1020 (with metformin)

(2012): Plosker GL, Drugs 72(17), 2289 [REVIEW]

(2012): Shah NK+, Pharmacotherapy 32(1), 80 [REVIEW]

(2012): Wilding JP+, Ann Intern Med 156(6), 405

(2009): Calado J, IDrugs 12(12), 785 [REVIEW]

(2009): Wilding JP+, Diabetes Care 32(9), 165613% (with insulin and oral antidiabetic agents)

Pollakiuria 

(2014): Kaku K+, Diabetes Ther 5(2), 4155%

(2009): Wilding JP+, Diabetes Care 32(9), 16568–13% (with insulin and oral antidiabetic agents)

Polyuria 

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print1%

Urinary frequency  3–4%

(package insert, 01/08/2014)

Urinary retention 

(2021): Crisafulli S+, Eur Urol Focus Jul, Online ahead of print (potential association)

Urinary tract infection 4–6%

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print1%

(2018): Puckrin R+, Acta Diabetol Feb, Epub ahead of print [REVIEW]

(2017): Dandona P+, Lancet Diabetes Endocrinol 5(11), 8644–7%

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print [REVIEW]7%

(2017): Johnston R+, Health Technol Assess 21(2), 1 [REVIEW]

(2016): Fioretto P+, Drugs Aging 33(7), 511

(2016): Frias JP+, Lancet Diabetes Endocrinol 4(12), 1004

(2016): Skolnik N+, Postgrad Med 128(4), 3562–5%

(2016): Yang W+, J Diabetes 8(6), 7964–7%

(2015): Bailey CJ+, Diabet Med 32(4), 531

(2015): Filippatos TD+, Ther Adv Endocrinol Metab 6(1), 29 [REVIEW]

(2015): Hinnen D, Ther Adv Endocrinol Metab 6(3), 92

(2015): Matthaei S+, Diabetes Care 38(3), 3656% (with metformin and sulfonylurea)

(2015): Matthaei S+, Diabetes Obes Metab 17(11), 107510% (with metformin and sulfonylurea)

(2015): Vivian EM, Am J Health Syst Pharm 72(5), 361 [REVIEW]

(2014): Anderson SL, Ther Adv Drug Saf 5(6), 242 [REVIEW]

(2014): Aylsworth A+, Ann Pharmacother 48(9), 1202 [REVIEW]

(2014): Jabbour SA+, Diabetes Care 37(3), 7407%

(2014): Ji L+, Clin Ther 36(1), 844–5%

(2014): Moses RG+, Australas Med J 7(10), 405 [REVIEW]

(2014): Strojek K+, Diabetes Ther 5(1), 2673–4% (with glimepiride)

(2014): Wilding JP+, Diabetes Obes Metab 16(2), 1248–14%

(2013): Albarran OG+, Med Clin (Barc) (Spanish) 141 Suppl 2, 36 [REVIEW]

(2013): Hinneburg I, Med Monatsschr Pharm (German) 36(4), 128

(2013): Johnsson KM+, J Diabetes Complications 27(5), 473

(2013): Kaku K+, Diabetes Obes Metab 15(5), 432

(2013): Nauck M+, Dtsch Med Wochenschr (German) 138 Suppl 1, S6 (with metformin)

(2013): Strojek K+, Dtsch Med Wochenschr (German) 138 Suppl 1, S164–7% (with glimepiride)

(2013): Wilding JP+, Dtsch Med Wochenschr (German) 138 Suppl 1, S27

(2012): Bolinder J+, J Clin Endocrinol Metab 97(3), 10203% (with metformin)

(2012): Musso G+, Ann Med 44(4), 375 [REVIEW]

(2012): Plosker GL, Drugs 72(17), 2289 [REVIEW]

(2012): Shah NK+, Pharmacotherapy 32(1), 80 [REVIEW]

(2012): Wilding JP+, Ann Intern Med 156(6), 405

(2011): Nauck MA+, Diabetes Care 34(9), 20157% (with metformin)

(2009): List JF+, Diabetes Care 32(4), 6505–12%

(2009): Wilding JP+, Diabetes Care 32(9), 16564% (with insulin and oral antidiabetic agents)

Vulvovaginal candidiasis 

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print3%

(2011): Nauck MA+, Diabetes Care 34(9), 20153% (with metformin)

Vulvovaginal pruritus 

(package insert, 01/08/2014)

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print3%

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print2%

Injection-site nodules 

(2016): Frias JP+, Lancet Diabetes Endocrinol 4(12), 1004

Injection-site reaction 

(2017): Lundkvist P+, Diabetes Obes Metab 19(9), 1276 (with exenatide)

Arthralgia 

(2014): Strojek K+, Diabetes Ther 5(1), 267<5% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20153% (with metformin)

Asthenia / fatigue 

(2021): Alguwaihes AM, Diabetes Ther Jun, Online ahead of print1%

(2009): Wilding JP+, Diabetes Care 32(9), 16564–8% (with insulin and oral antidiabetic agents)

Back pain 3–4%

(2014): Kaku K+, Diabetes Ther 5(2), 4154%

(2011): Nauck MA+, Diabetes Care 34(9), 20155% (with metformin)

(2009): Wilding JP+, Diabetes Care 32(9), 16568–13% (with insulin and oral antidiabetic agents)

Pain in extremities 2%

(2009): Wilding JP+, Diabetes Care 32(9), 16564–8% (with insulin and oral antidiabetic agents)

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury 

(2017): Jabbour S+, Diabetes Obes Metab Sep, Epub ahead of print3%

(2016): Skolnik N+, Postgrad Med 128(4), 3562–4%

Renal failure 

(2017): Perlman A+, Nutr Metab Cardiovasc Dis 27(12), 11085%

(2015): Cefalu WT+, Diabetes Care 38(7), 1218

Bronchitis 

(2014): Strojek K+, Diabetes Ther 5(1), 267<3% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20155% (with metformin)

Cough 

(2014): Strojek K+, Diabetes Ther 5(1), 267<3% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20154% (with metformin)

Influenza 2–3%

(2011): Nauck MA+, Diabetes Care 34(9), 20157% (with metformin)

(2009): Wilding JP+, Diabetes Care 32(9), 16564% (with insulin and oral antidiabetic agents)

Nasopharyngitis 6–7%

(2017): Dandona P+, Lancet Diabetes Endocrinol 5(11), 86412–14%

(2014): Anderson SL, Ther Adv Drug Saf 5(6), 242 [REVIEW]

(2014): Aylsworth A+, Ann Pharmacother 48(9), 1202 [REVIEW]

(2014): Kaku K+, Diabetes Ther 5(2), 41525%

(2014): Strojek K+, Diabetes Ther 5(1), 2674–8% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 201511% (with metformin)

(2009): Wilding JP+, Diabetes Care 32(9), 16568% (with insulin and oral antidiabetic agents)

Pharyngolaryngeal pain 

(2009): Wilding JP+, Diabetes Care 32(9), 16568%

Upper respiratory tract infection 

(2017): Dandona P+, Lancet Diabetes Endocrinol 5(11), 8645%

(2014): Kaku K+, Diabetes Ther 5(2), 4155%

(2014): Strojek K+, Diabetes Ther 5(1), 2673–5% (with glimepiride)

(2011): Nauck MA+, Diabetes Care 34(9), 20156% (with metformin)

(2009): Wilding JP+, Diabetes Care 32(9), 16564–8% (with insulin and oral antidiabetic agents)

Adverse effects 

(2019): Araki E+, Diabetes Obes Metab Nov, Epub ahead of print73–82%

(2017): Araki E+, Diabetes Obes Metab 19(4), 56283%

(2016): Yang W+, J Diabetes 8(6), 7962% (serious)

(2014): Ji L+, Clin Ther 36(1), 8461–62%

(2014): Ptaszynska A+, Drug Saf 37(10), 815

(2013): Kaku K+, Diabetes Obes Metab 15(5), 43254%

(2013): Strojek K+, Dtsch Med Wochenschr (German) 138 Suppl 1, S166–7% (serious) (with glimepiride)

(2012): Bolinder J+, J Clin Endocrinol Metab 97(3), 10207% (with metformin)

(2011): Strojek K+, Diabetes Obes Metab 13(10), 9286–7% (serious) (with glimepiride)

(2010): Bailey CJ+, Lancet 375(9733), 2223 (serious / 4 cases) (with metformin)

Cancer 

(2015): Hinnen D, Ther Adv Endocrinol Metab 6(3), 92 (bladder)

Death 

(2017): Esteban-Jimenez O+, Semergen Nov, Epub ahead of print1%

Dipsia (thirst) / polydipsia 

(2014): Kaku K+, Diabetes Ther 5(2), 4154%

(2009): Wilding JP+, Diabetes Care 32(9), 16562–4% (with insulin and oral antidiabetic agents)

Infection <10%

(package insert, 01/08/2014)

Tooth decay 

(2014): Kaku K+, Diabetes Ther 5(2), 4154%



Adverse reactions attributed to entire drug class Sodium-glucose co-transporter 2 (SGLT2) inhibitor

Photosensitivity 

(2017): Raschi E+, Nutr Metab Cardiovasc Dis 27(12), 1098

Rash 

(2017): Raschi E+, Nutr Metab Cardiovasc Dis 27(12), 1098

Urticaria / hives 

(2017): Raschi E+, Nutr Metab Cardiovasc Dis 27(12), 1098

Acute coronary syndrome 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

Hypotension 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

(2014): Mikhail N, World J Diabetes 5(6), 854 [REVIEW]

Vertigo / dizziness 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

(2014): Mikhail N, World J Diabetes 5(6), 854 [REVIEW]

Dehydration  

(2017): Trujillo JM+, Pharmacotherapy 37(4), 481

Diabetic ketoacidosis 

(2021): Zheng C+, Cardiovasc Diabetol 20(1), 83 [REVIEW] (association)

(2019): Nappi F+, Medicina (Kaunas) 55(8), pii:E462 (1 case)

(2019): Shi FH+, Front Pharmacol Sep, 10:1066 [REVIEW]

(2019): Wang CT+, J Formos Med Assoc Dec, Epub ahead of print (1 case)Geriatric

(2018): Bonora BM+, Diabetes Obes Metab 20(1), 25 [REVIEW]

(2018): Singh M+, Curr Drug Saf Feb, Epub ahead of print [REVIEW]

(2017): Burke KR+, Pharmacotherapy 37(2), 187 [REVIEW]

(2017): Chen J+, Sci Rep 7, Epub [REVIEW]

(2017): Mizuno A+, Rev Med Suisse (French) 13(565), 1164 [REVIEW] (euglycemic)

(2017): Moumouni ANA+, Fundam Clin Pharmacol Nov, Epub ahead of print

(2017): Trujillo JM+, Pharmacotherapy 37(4), 481

(2016): Scheen AJ, Curr Diab Rep 16(10), 92 [REVIEW]

Fluid depletion / volume depletion 

(2021): Rahhal A+, Curr Probl Cardiol Sep, Online ahead of print [REVIEW]

Hyperglycemia (includes glucose increased) 

(2019): Wang CT+, J Formos Med Assoc Dec, Epub ahead of print (1 case)Geriatric

Hypoglycemia 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

(2019): Shi FH+, Front Pharmacol Sep, 10:1066 [REVIEW]

Nausea 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

Genital mycotic infection 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection73%

(2019): Shi FH+, Front Pharmacol Sep, 10:1066 [REVIEW]

(2017): Trujillo JM+, Pharmacotherapy 37(4), 481

(2016): Gomez-Fernandez P+, Med Clin (Barc) 147 Suppl 1, 44

(2016): Scheen AJ, Curr Diab Rep 16(10), 92 [REVIEW]

(2015): Scheen AJ, Drugs 75(1), 33

(2014): Halimi S+, Diabetes Metab 40(6 Suppl 1), S28

(2014): Mikhail N, World J Diabetes 5(6), 854 [REVIEW]

(2014): Nauck MA, Drug Des Devel Ther 8, 1335

(2012): Rosak C+, MMW Fortschr Med (German) 154 Suppl 4, 95 [REVIEW]

Genital pruritus 

(2016): Sosale B+, J Assoc Physicians India 64(9), 404%

Polyuria 

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

Urinary frequency  

(2019): Shi FH+, Front Pharmacol Sep, 10:1066 [REVIEW]

(2014): Halimi S+, Diabetes Metab 40(6 Suppl 1), S28

Urinary tract infection 

(2021): Zheng C+, Cardiovasc Diabetol 20(1), 83 [REVIEW] (association)

(2019): Mirabelli M+, J Diabetes Res Nov, eCollection

(2018): Singh M+, Curr Drug Saf Feb, Epub ahead of print [REVIEW]

(2017): Trujillo JM+, Pharmacotherapy 37(4), 481

(2014): Halimi S+, Diabetes Metab 40(6 Suppl 1), S28

(2014): Mikhail N, World J Diabetes 5(6), 854 [REVIEW]

(2014): Nauck MA, Drug Des Devel Ther 8, 1335

(2013): Raskin P, Diabetes Metab Res Rev 29(5), 347 [REVIEW]

(2013): Vasilakou D+, Ann Intern Med 159(4), 262 [REVIEW]

Fractures 

(2018): Singh M+, Curr Drug Saf Feb, Epub ahead of print [REVIEW]

(2017): Trujillo JM+, Pharmacotherapy 37(4), 481

(2016): Scheen AJ, Curr Diab Rep 16(10), 92 [REVIEW]

Adverse effects 

(2021): Martínez-Vizcaíno V+, J Clin Med 10(12), 2713 [REVIEW]

(2021): Zhou X+, Front Pharmacol Dec, eCollection

(2020): Cai Y+, Expert Opin Drug Saf Sep, Online ahead of print [REVIEW] (with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers)

(2017): Raschi E+, Nutr Metab Cardiovasc Dis 27(12), 1098

Cancer 

(2018): Singh M+, Curr Drug Saf Feb, Epub ahead of print [REVIEW]

Page last updated 08/05/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top